CS Paper Radar

From Benchmarks to the Bench: Preference, Correspondence and Selectivity in Bidirectional Drug-Target Screening

Jiangjie Qiu, Chengrui Xu, Xiaonan Wang

cs.LG ·submitted 2026-11-19 16:34 UTC · v1
benchmark

Abstract

Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing. Drug-target interaction (DTI) models can rank vast numbers of drug-target pairs, but limited experimental capacity restricts testing to a small number of candidates. We compared the bidirectional recommendations of 13 released systems across 711 molecular structures of FDA-approved drugs and 614 human proteins. For the same target or drug, pairs of models produced completely disjoint Top-10 molecule and protein lists in 77.8% and 70.1% of comparisons, respectively. Even where recommendations overlapped, agreement between some systems largely reflected recurring preferences for the same candidates. Published inhibition measurements for 79 molecules and 65 kinases revealed that some systems enriched active candidates, yet their hit yields changed little when recommendations were matched to different drugs or targets, whereas other systems lost substantially more hits. Some of the former systems also rarely ranked both molecules and kinases correctly when two drugs favoured different kinases. We further retrained the same architecture on the same data, with the training objective fixed and random seeds varied. Despite similar test performance, mean pairwise Top-10 overlap on a separate screening catalogue was about two candidates. Our study moves DTI model evaluation beyond benchmark performance to assess whether model predictions can guide meaningful experimental decisions in drug discovery and target identification.

Comment
18 pages, 5 figures and 1 table

Closest papers

Nearest neighbours by meaning across the whole index.

Beyond Random Splits: Evaluating Drug-Target Affinity Models Under Chemically and Biologically Motivated Distribution Shifts Copy

cs.LG ·2026-10-02 ·Minjae Chung, Clara Li, Malar Paavai Muthukumaran, Shaunna Wang, Aniket Ramkrishnan Iyer +6 more
published similarity 0.72
Abstract · Accepted to the NeurIPS 2026 Workshop on AI for Drug Discovery (AI4DD)

Drug-target affinity (DTA) prediction is widely used to prioritize candidate compounds before costly experimental screening. DTA models are often compared under a single data split, even though deployment may require extrapolation to new chemical series, new protein targets, or both. We ask whether the distribution shift used for evaluation changes which architecture appears best. We curate 718,800 unique drug-protein pairs from the ChEMBL and BindingDB datasets. We compare a Morgan-fingerprint + protein-CNN baseline with 12 controlled architectures that combine four drug representations with three ESM-2 interaction modes. Mean validation RMSE increases from 0.950 and 0.945 under scaffold and fingerprint-cluster OOD to 1.299 and 1.321 under protein-cluster and dual OOD. Model rankings are similar across the two chemical shifts (tau = 0.79), but agreement with scaffold OOD falls under protein OOD (tau = 0.39) and reverses under dual OOD (tau = -0.55). Held-out evaluation, repeated seeds, group-aware bootstrap analysis, and a size-matched control support the same conclusion: architecture selection depends on the form of extrapolation, not only on average error or training-set size. DTA benchmarks should therefore match the chemical and target shifts expected at deployment.

0.24

PETA:Parameter-Efficient Test-Time Adaptation for Virtual Screening

cs.LG ·2026-08-20 ·Jia-Qi Lin, Yinghua Yao, Chang-Dong Wang, Yew-Soon Ong, Yuangang Pan
similarity 0.68
Abstract

Accurately ranking active ligands for a target protein pocket from massive chemical libraries remains a central challenge in virtual screening. DrugCLIP and its recent extensions substantially accelerate this process by encoding protein pockets and molecules into a shared embedding space. Despite this progress, further performance improvements typically require retraining the entire model, incurring substantial computational overhead and making target-specific customization inefficient. In this work, we formulate the specialization of pretrained virtual screening models to individual pockets as a test-time adaptation problem and propose PETA, a parameter-efficient framework that directly adapts pretrained model at test time. Given a target pocket, PETA constructs pocket-specific negatives through molecular diffusion and chemical validity filtering, and further moves them toward the reference ligand retrieved from structural databases via embedding-space mixup to create more challenging ranking tasks. A ranking objective then places greater emphasis on suppressing high-scoring invalid candidates that could contaminate the top-ranked screening results, providing structured supervision for lightweight adaptation. Experiments across diverse benchmarks demonstrate that this lightweight, pocket-specific adaptation outperforms both pretrained and fully retrained baselines while updating only the LayerNorm parameters, which account for approximately $0.03\%$ of the full model.

0.16

SpecOpt: Contact-Diff Reasoning for Agentic Molecule Optimization Toward Binding Specificity

cs.AI ·2026-09-18 ·Thao Nguyen, Heng Ji
benchmark similarity 0.67
Abstract

Off-target protein binding is a major source of adverse effects for small-molecule drugs, yet most structure-based molecular design methods focus on generating selective compounds de novo rather than improving the selectivity of existing, well- characterized drugs. We introduce specificity optimization (SpecOpt), a molecular design task that seeks constrained structural modifications to an existing compound that increase its binding preference for an intended target over known off-targets while preserving its structural identity and drug-like properties. To enable systematic evaluation, we construct a ChEMBL-derived benchmark from compound-target interaction data, identifying intended targets through curated drug-mechanism annotations and off- targets through measured activities. We then develop an agentic framework that docks each compound against its intended target and off-targets, compares the resulting poses through residue-aware atom-protein contacts, and provides these differential interactions to a large language model to propose targeted structural modifications. Candidates are retained only if they satisfy molecular similarity, ADMET, and target-off-target docking selectivity criteria. On 915 compounds, the agent improves the target- off-target binding gap for 84.8% of compounds, shifting the mean gap from -0.72 to +0.47 kcal/mol while maintaining a mean Tanimoto similarity of 0.72 to the starting compounds. Ablation studies identify residue-specific contact information as the critical optimization signal: replacing residue identities with binary contact indicators eliminates improvement on all 29 ablation compounds. These results establish SpecOpt as a distinct molecular design problem and demonstrate residue-aware differential interactions as an effective signal for improving the specificity of existing compounds.

0.08

ProbeMatchDTI: Probe-Driven Multi-Scale Biochemical Pattern Matching for Drug-Target Interaction Prediction

cs.LG cs.AI ·2026-09-02 ·Quan Hao, Mengyue Fan, Zifan Dong, Youru Li, Jianduo Zhao +6 more
code/data similarity 0.66
Abstract

Drug-target interaction (DTI) prediction is an important task in AI-driven drug discovery. Although recent biochemical representation learning methods have improved DTI prediction, their passive feature aggregation tends to favor dominant molecular patterns while suppressing weak yet binding-relevant signals, such as functional groups and residue-context patterns, limiting the modeling of multi-scale biochemical correspondences. To address this issue, we propose ProbeMatchDTI, a pattern-probe-driven framework comprising IterProbe and BindingProbe. IterProbe explicitly retains contextual states across refinement depths and uses learnable probes to select them at each position before cross-entity matching, thereby preserving weak biochemical patterns and strengthening associations among functional groups, local motifs, and molecular scaffolds. BindingProbe then characterizes cross-entity drug-protein complementarity at local biochemical-unit and whole-pair levels, jointly modeling fine-grained interactions and multi-scale correspondences while preserving weaker binding-relevant associations. Extensive experiments demonstrate the superiority of ProbeMatchDTI, achieving 2.0% and 0.5% higher AUC-ROC on BindingDB and DrugBank, respectively. Feature-level pattern analyses further characterize its probe-driven behavior in cross-scale biochemical pattern matching. We further connect ProbeMatchDTI predictions with an evidence-guided downstream drug-discovery workflow, demonstrating their utility for candidate refinement and validation planning. Our code is available at https://github.com/developer-hq/ProbeMatchDTI

0.28

On the Selectivity of Generative Models in Structure-Based Drug Design

cs.LG cs.AI ·2026-10-16 ·Ella Miray Rajaonson, Jungyoon Lee, William Chau, Alan Aspuru-Guzik, Benjamin Sanchez-Lengeling +3 more
top venuebenchmarkcode/data similarity 0.66
Abstract · Accepted as a Presentation at the Neural Information Processing Systems 2026

Designing small-molecule drugs that selectively bind to a target protein while avoiding unintended interactions with other proteins is essential for reducing side effects that contribute substantially to clinical attrition. Although structure-based drug design (SBDD) has advanced rapidly with deep learning, most generative models still optimize binding to a single target and disregard selectivity due to limited training data and unknown off-target interactions. Motivated by this gap, we introduce SELECTBENCH, a comprehensive benchmark assessing the selectivity of generative SBDD models. SELECTBENCH provides three curated evaluation tasks reflecting different real-world drug discovery scenarios: literature-based case studies, safety screening panels used in pharmaceutical development, and large-scale structure-based evaluation sets. We further introduce a suite of metrics to quantify selectivity and conduct a systematic evaluation of nine representative SBDD models, including methods explicitly trained for selectivity and widely-used inference-time guidance techniques. Our results show that even selectivity-trained models achieve only modest off-target discrimination and inference-time guidance provides limited gains, underscoring the need for method improvement. SELECTBENCH provides both a characterization of where current generative SBDD stands on selectivity and an open, extensible platform to accelerate progress. The benchmark is available at https://github.com/lovetaro/selectbench.

0.44

ColdDDI: Evaluating Knowledge Utilization in Cold-Start Drug-Drug Interaction Prediction

cs.LG cs.CL ·2026-10-04 ·Jiheng Liang, Chen Zhao, Di Wu, Chenyang Bu, Yunpeng Hong +2 more
publishedbenchmarkcode/data similarity 0.66
Abstract · Accepted at NeurIPS 2026 (poster). Code: https://github.com/0217ljh/ColdDDI-NeurIPS2026

Cold-start drug-drug interaction (DDI) prediction tests whether models can identify clinically significant interactions for drugs without training-time interaction history. Existing benchmarks mostly report aggregate edge-prediction scores, leaving a key evaluation question unanswered: when models receive molecular, textual, or knowledge-graph (KG) evidence, do they actually use the evidence that pharmacologically supports the interaction? We introduce ColdDDI, a reconstructible diagnostic benchmark built from DrugBank 5.1.13, with 1,900 approved small-molecule drugs and 565,731 positive DDI pairs. ColdDDI evaluates pairs with zero, one, or two unseen drugs. It also annotates each interaction by whether it changes drug exposure or drug effect, and by whether the biomedical knowledge graph contains shared enzymes, transporters, or targets that can plausibly mediate the interaction. These annotations separate evidence availability from predictive dependence. We evaluate eight conventional DDI methods and 13 LLMs; for open-weight LLMs, we test five prompt patterns and use masking, drug replacement, and channel-sensitivity metrics to probe knowledge utilization. ColdDDI exposes that, in the hardest split where both drugs are unseen, the main performance divide is mediator availability. A fine-tuned 1B LLM recovers 89-93% of interactions with a shared enzyme, transporter, or target, but only 40-62% without such a mediator. More importantly, KG-provided evidence is not always used; several KG-augmented baselines change little when the shared mediator is masked or disrupted, whereas fine-tuned LLMs respond strongly to this intervention. Thus, ColdDDI evaluates knowledge utilization rather than knowledge access alone, showing where cold-start DDI models rely on mechanistic evidence and where they fail despite receiving it. Code is available at https://github.com/0217ljh/ColdDDI-NeurIPS2026.

0.39

D2ML: Models for Direct-to-Biology Small Molecule Screening

cs.LG q-bio.BM ·2026-10-29 ·AkshatKumar Nigam, Neri Amara, Hillary Dequina, Dyana Kenanova, Seth Malmersjo +5 more
published similarity 0.65
Abstract · NeurIPS 2026 Workshop on AI for Drug Discovery (AI4DD)

Direct-to-biology (D2B) screening enables rapid testing of newly synthesized molecules without purification. However, uncertain concentrations in crude mixtures and limited purified-compound measurements complicate the use of these data in machine learning. Here we show that models tailored to the structure of D2B data can improve prediction and guide the discovery of more potent and selective compounds. Our assay-aware models predict activity from single-point screens, relative potency across targets from crude dose-response assays, and absolute potency from purified-compound measurements. For crude assays, potency ratios between targets tested from the same well can retain selectivity information despite uncertain concentrations. A joint model that shares information across stages and balances their contributions to training improved predictions over separate neural networks. The largest gain was in crude dose-response selectivity prediction, where rank correlation increased from 0.27 to 0.40. In a separate experiment, independently trained models guided the selection of 84 new compounds to improve ROS1 potency while limiting activity against the anti-target TRKB. Synthesis and testing identified compounds that extended the measured Pareto front, achieving better combinations of potency and selectivity than those in the training data. The most selective new compound achieved a ROS1 IC50 of 14.7 nM and 233-fold selectivity over TRKB. By comparison, the most selective training compound had a ROS1 IC50 of 20.3 nM and 79-fold selectivity. ATLAS provides the experimental setting for this approach, supporting synthesis and screening of 1,000-10,000 model-selected compounds in two- to three-week cycles. Together, these results show how assay-aware learning can use the full D2B assay sequence to guide multi-objective molecular optimization.

0.16

DPTM-DT: Dual-Pretrained Transformer Multitask Representation Learning for Drug-Target Prediction

cs.LG cs.AI ·2026-08-28 ·Ge Kong
code/data similarity 0.64
Abstract

Drug-target relation prediction supports candidate screening, drug repositioning, and mechanism analysis. Existing models often use incomplete drug or protein representations, model cross-modal interactions shallowly, or train affinity regression and interaction classification separately, although these tasks describe closely related views of the same drug-target pair. This paper presents DPTM-DT, a dual-pretrained Transformer framework for multitask drug-target prediction. DPTM-DT combines GROVER molecular graph embeddings, ESM protein language-model embeddings, and CTD physicochemical descriptors, then exchanges drug-target information through bidirectional cross-modal attention. A shared pair representation is used for continuous affinity regression, high-affinity binary classification, and six-level affinity classification. Experiments on Davis and KIBA cover random 80/20 and DeepDTA-style standard splits. On the random 80/20 split, DPTM-DT achieves MSE/CI values of 0.193/0.917 on Davis and 0.120/0.918 on KIBA. It also reports binary AUPR/MCC values of 0.727/0.654 and 0.798/0.689, and six-class Macro-F1/Top-2 values of 0.800/0.932 and 0.815/0.962 on Davis and KIBA, respectively. Across the reported regression, binary classification, and multiclass classification settings, DPTM-DT achieves the best overall performance among the compared methods. Results under the standard split show the same relative trend. Ablations indicate that dual target representation, gated fusion, and cross-modal attention each contribute to the final performance. Code and supplementary materials are available at: anonymous.4open.science/r/DPCM-DT-74E0.

0.26